MEDANTA

As of 14 November 2025, the valuation grade for Global Health has moved from very expensive to expensive. The company is currently considered overvalued, with a PE ratio of 52.58, an EV to EBITDA of 32.56, and a Price to Book Value of 9.31. In comparison to its peers, Apollo Hospitals is rated attractive with a PE of 63.77 and an EV to EBITDA of 33.53, while Narayana Hrudaya is also expensive with a PE of 45.39 and an EV to EBITDA of 28.01. Despite a recent decline in stock price, with a 1-month return of -13.27% compared to a 3.09% return for the Sensex, Global Health's financial metrics suggest it is trading at a premium relative to its industry peers. The company's high PEG ratio of 2.31 further indicates that its growth expectations may not justify its current valuation. Overall, Global Health appears to be overvalued in the current market environment.